Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees

H Samples, AR Williams, M Olfson, S Crystal - Journal of substance abuse …, 2018 - Elsevier
Introduction Recent US trends demonstrate sharp rises in adverse opioid-related health
outcomes, including opioid use disorder (OUD), overdose, and death. Yet few affected …

Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder

AR Williams, H Samples, S Crystal… - American Journal of …, 2020 - Am Psychiatric Assoc
Objective: Although buprenorphine treatment reduces risk of overdose and death in opioid
use disorder, most patients discontinue treatment within a few weeks or months. Adverse …

The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion

A Meinhofer, AE Witman - Journal of health economics, 2018 - Elsevier
We estimate the effect of health insurance coverage on opioid use disorder treatment
utilization and availability by exploiting cross-state variation in effective dates of Medicaid …

Association of Medicaid expansion with opioid overdose mortality in the United States

N Kravitz-Wirtz, CS Davis, WR Ponicki… - JAMA network …, 2020 - jamanetwork.com
Importance The Patient Protection and Affordable Care Act (ACA) permits states to expand
Medicaid coverage for most low-income adults to 138% of the federal poverty level and …

[PDF][PDF] The economic burden of the opioid epidemic on states: the case of Medicaid

DL Leslie, DM Ba, E Agbese, X Xing… - Am J Manag …, 2019 - ajmc.s3.amazonaws.com
OUD affects 2.5 million Americans1 and is prevalent across all age groups and
backgrounds. It has contributed to increasing injection drug use as well as the spread of …

Medications for opioid use disorder: bridging the gap in care

ND Volkow - The Lancet, 2018 - thelancet.com
Comment 286 www. thelancet. com Vol 391 January 27, 2018 medications and is the most
frequently prescribed medication for opioid use disorder globally. 14 However, in the USA …

State Funding For Substance Use Disorder Treatment Declined In The Wake Of Medicaid Expansion: Study examines state funding for substance use disorder …

CM Andrews, OM Hinds, F Lozano-Rojas… - Health …, 2023 - healthaffairs.org
The US continues to grapple with an escalating epidemic of opioid-related overdose and
mortality. State funds, which are the second-largest source of public funding for substance …

Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017–21: study examines insurance restrictions on buprenorphine treatment for …

B Andraka-Christou, KI Simon, WD Bradford… - Health …, 2023 - healthaffairs.org
Buprenorphine is a treatment medication that decreases mortality risks among people with
opioid use disorder (OUD). Despite its efficacy, buprenorphine is underused in the US …

Perceptions and practices addressing diversion among US buprenorphine prescribers

LA Lin, MR Lofwall, SL Walsh, AJ Gordon… - Drug and Alcohol …, 2018 - Elsevier
Background While there has been a dramatic increase in prescribing of buprenorphine for
the treatment of opioid use disorder in the US, little is known about prescribers' attitudes and …

The impacts of the ACA Medicaid expansions on cancer screening use by primary care provider supply

W Lyu, GL Wehby - Medical care, 2019 - journals.lww.com
Background: Recent studies of the impacts of the Affordable Care Act (ACA) Medicaid
expansions on cancer screening use have mostly found insignificant effects. We posit that …